The role of neoadjuvant imatinib in gastrointestinal stromal tumor patients: 20 years of experience from a tertial referral center

Surgery is the cornerstone of gastrointestinal stromal tumor (GIST) treatment, and adjuvant therapy with imatinib has improved survival for high‐risk tumors. The use of imatinib preoperatively has been increasing, but efficacy and impact on patient outcomes have not been formally investigated. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Renberg, Sara, Zhang, Yifan, Karlsson, Fredrik, Bränström, Robert, Åhlen, Jan, Jalmsell, Li, Linder‐Stragliotto, Christina, Haglund de Flon, Felix, Papakonstantinou, Andri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545454/
https://www.ncbi.nlm.nih.gov/pubmed/35478315
http://dx.doi.org/10.1002/ijc.34052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545454/
https://www.ncbi.nlm.nih.gov/pubmed/35478315
http://dx.doi.org/10.1002/ijc.34052

Ejemplares similares